Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endo oxymorphone ER data

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Endo's extended-release oxymorphone product shows statistically significant results in a Phase III study of patients with moderate to severe low back pain, the firm reports Oct. 3. In the 12-week, 142-patient study of opioid-experienced patients, oxymorphone ER showed a significant change in average pain intensity compared to placebo (p<0.0001). The results are similar to those from an initial Phase III trial in opioid-naïve patients; Endo announced the results of that initial pivotal trial, conducted under a special protocol assessment, in August. Endo continues to project a complete response to dual "approvable" letters for its ER and immediate-release oxymorphone formulations in 2006...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS003068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel